恶性肿瘤患者的出血素质（作者译）

[Hemorrhagic diathesis in patients with malignant neoplasms (author's transl)].

作者信息

Zöller H, Gross W, Schreiner W

出版信息

Med Klin. 1979 Nov 16;74(46):1716-20.

Abstract

Clotting analysis in 30 patients with bleeding complications in malignant hematological diseases revealed the following troubles: The global tests, Quick's index and partial thromboplastin time markedly differed from normal. Activity of clotting factors revealed hypo- or hyperfibrinogenemia, disturbances of the prothrombin complex (factors II, VII, IX and X), decrease of factors V, VIII, XII. Factor XI (= PTA) was not diminished in any case. Regarding the fibrin-stabilizing factor (factor XIII), its activity was significantly decreased in 30 patients with solid tumors and in 30 patients with hemoblastoses. Faulty clotting balance was characterized by hyperfibrinolysis or disseminated intravascular coagulation (DIC) accompanied by reactive hyperfibrinolysis. About one quarter of the patients with malignant disturbances of the hematopoetic system demonstrated (mostly amegacaryocyte) thrombocytopenia. Finally, treatment of bleeding complications in malignant neoplastic diseases is pointed out.

摘要

对30例恶性血液病出血并发症患者的凝血分析显示出以下问题：全血凝固试验、奎克指数和部分凝血活酶时间与正常情况有显著差异。凝血因子活性显示有低纤维蛋白原血症或高纤维蛋白原血症、凝血酶原复合物（因子II、VII、IX和X）紊乱、因子V、VIII、XII减少。因子XI（=PTA）在任何情况下均未减少。关于纤维蛋白稳定因子（因子XIII），其活性在30例实体瘤患者和30例成血细胞增多症患者中显著降低。凝血平衡异常的特征是纤维蛋白溶解亢进或弥散性血管内凝血（DIC）并伴有反应性纤维蛋白溶解亢进。约四分之一的造血系统恶性疾病患者表现出（大多为无巨核细胞）血小板减少。最后，指出了恶性肿瘤疾病出血并发症的治疗方法。